Isotope | Jotup

ZAP Surgical Announces Additional Installation of Its State-of-the-Art ZAP-X Brain Tumor Treatment System in New York State

Retrieved on:

Tuesday, March 5, 2024

NSG is a free-standing, privately-owned clinic serving Central New York, the New York Southern Tier, and Northern Pennsylvania.

Key Points:

NSG is a free-standing, privately-owned clinic serving Central New York, the New York Southern Tier, and Northern Pennsylvania.
System installation is expected to begin in July, with first patient treatments estimated to commence before the end of the year.
“As a procedure with no incisions and no pain, ZAP-X radiosurgery treats patients in what often requires only a single brief outpatient visit.
This novel approach aims to maximally safeguard healthy brain tissue and preserve patient cognitive function.

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

Retrieved on:

Tuesday, February 20, 2024

The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).

Key Points:

The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).
In the 4 consecutive patients with metastatic prostate cancer who were evaluated, when looking at radiologic progression free survival (rPFS), 2 patients had not progressed at 24 and 18 months of follow-up.
177Lu-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted radiopharmaceutical for the treatment of prostate cancer, and the lead candidate in Blue Earth Therapeutics’ development of next generation therapeutic radiopharmaceuticals.
“These promising clinical data give us further optimism in advancing 177Lu-rhPSMA forward in clinical development, with the hope to help treat patients with metastatic prostate cancer.

Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities

Retrieved on:

Tuesday, March 5, 2024

Diagnosis, Isotope, Therapy, PET, Research, SPECT, Pharmaceutical industry

With the new facility, Ariceum has more than ~200m² of laboratory space (cold biology/chemistry lab; radioactive lab) to which a further ~60m² of changing lock and storage space can be added.

Key Points:

With the new facility, Ariceum has more than ~200m² of laboratory space (cold biology/chemistry lab; radioactive lab) to which a further ~60m² of changing lock and storage space can be added.
Furthermore, the new laboratory will allow Ariceum to conduct non-clinical pharmacology studies for detailed characterization of its first-in-class development candidates.
Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, said: "Following 15 months of construction at our headquarters in Berlin, we are delighted to have opened our brand new, advanced laboratory space.
We are very grateful to our team in Berlin who have pushed hard to bring these construction plans to fruition."

Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities

Retrieved on:

Tuesday, March 5, 2024

Diagnosis, Isotope, Therapy, PET, Research, SPECT, Pharmaceutical industry

With the new facility, Ariceum has more than ~200m² of laboratory space (cold biology/chemistry lab; radioactive lab) to which a further ~60m² of changing lock and storage space can be added.

Key Points:

With the new facility, Ariceum has more than ~200m² of laboratory space (cold biology/chemistry lab; radioactive lab) to which a further ~60m² of changing lock and storage space can be added.
Furthermore, the new laboratory will allow Ariceum to conduct non-clinical pharmacology studies for detailed characterization of its first-in-class development candidates.
Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, said: "Following 15 months of construction at our headquarters in Berlin, we are delighted to have opened our brand new, advanced laboratory space.
We are very grateful to our team in Berlin who have pushed hard to bring these construction plans to fruition."

Used Nuclear Fuel Recycling Agreement Signed by Orano and SHINE Technologies

Retrieved on:

Thursday, February 29, 2024

SHINE, MOU, Recycling, Toxicity, Shine Technologies, Pupa, Isotope, CFR, Uranium mining

BETHESDA, Md., Feb. 29, 2024 /PRNewswire/ -- Orano and SHINE Technologies signed a Memorandum of Understanding (MOU) this week to cooperate in the development of a U.S. pilot plant with commercial-scale technology for recycling used nuclear fuel from light water reactors.

Key Points:

BETHESDA, Md., Feb. 29, 2024 /PRNewswire/ -- Orano and SHINE Technologies signed a Memorandum of Understanding (MOU) this week to cooperate in the development of a U.S. pilot plant with commercial-scale technology for recycling used nuclear fuel from light water reactors.
"For this initiative with SHINE, we bring more than 55 years of experience transporting and recycling used nuclear fuel in France and managing used fuel in the U.S."
"Our goal is to stand up an operational pilot facility by the early 2030s.
"It is time for the U.S. to seriously consider recycling used nuclear fuel," said Jean-Luc Palayer, CEO of Orano USA.
Recycling used nuclear fuel into useful products will significantly reduce the mass, volume, and toxicity of the remaining nuclear material for permanent disposal.

ASP Isotopes Inc. Provides Update on Plans to Spin-Out its Wholly Owned Subsidiary, Quantum Leap Energy

Retrieved on:

Friday, February 16, 2024

Lithium, Engineering, Nickel, Uranium, Ytterbium, Isotope, SMR, Nuclear Energy Institute, ASP, Microsoft, Nuclear energy, ASPI, License, Void coefficient, HALEU, Uranium mining

WASHINGTON, Feb. 16, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or “ASPI” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, announced today an update on its previously disclosed intention to spin-out its wholly owned subsidiary, Quantum Leap Energy LLC (“QLE”), as a separate public company. ASPI is planning to list QLE on a national exchange and distribute a portion of QLE’s common equity to ASPI’s stockholders as of a future record date, anticipated to be completed by year-end, in each case subject to obtaining applicable approvals and consents and complying with applicable rules and regulations and public market trading and listing requirements.

Key Points:

- ASP Isotopes plans to spin a portion of Quantum Leap Energy’s common equity to ASP Isotopes' stockholders as of a future record date, in a tax efficient manner.
- ASP Isotopes licenses rights to technology related to the enrichment of nuclear fuels to Quantum Leap Energy.
ASPI to receive a 10% perpetual royalty on all revenues of Quantum Leap Energy.
- ASPI and QLE continue to work with potential customers to help resolve the current nuclear fuel supply chain issues.

LIS Technologies Inc. Becomes a Member of the American Nuclear Society (ANS), the Premier Nuclear Science Organization

Retrieved on:

Friday, February 9, 2024

ANS, American Nuclear Society, Nuclear energy, Isotope, Organization, Society, United, LIS, Patent, Uranium

Figure 1 - LIS Technologies Inc.

Key Points:

Figure 1 - LIS Technologies Inc.
Today, ANS has made, and continues to make, important contributions to the use of nuclear science and technology, and consequently to the larger society beyond ANS.
The Company anticipates its membership to play a pivotal role in shaping the conversation surrounding the technological innovations poised to rejuvenate and invigorate the nuclear energy sector in the United States.
This proprietary laser-based technique offers greater energy-efficiency and has the potential to be deployed with highly competitive capital and operational costs.

LIS Technologies Inc. Welcomes Expert Talent to help Propel the Rebirth of the CRISLA Laser Enrichment Technology

Retrieved on:

Wednesday, February 7, 2024

LIS, Isotope, Patent, AVLIS, DUV, Welding, Laboratory, Electronics, Laser, Uranium, CO2, LLNL, EUV, Technician, ASML, 3D printing

Kevin Duenow will take on the role of Senior Systems Engineer and Adam Duenow joins as a Laboratory Technician.

Key Points:

Kevin Duenow will take on the role of Senior Systems Engineer and Adam Duenow joins as a Laboratory Technician.
These appointments are important to the Company's strategic initiative to reinvigorate CRISLA technologies with a clear and defined focus.
In the early 90’s he worked as a Laser and Electronics Engineer on the AVLIS laser enrichment program at LLNL.
This proprietary laser-based technique offers greater energy-efficiency and has the potential to be deployed with highly competitive capital and operational costs.

US Nuclear’s Medical Isotope Production to Revolutionize Healthcare

Retrieved on:

Tuesday, January 30, 2024

Isotope, Myocardial perfusion imaging, Nuclear medicine, US Nuclear Corp, Health, Diagnosis, Medicine, Facial muscles, United, Approximation error, Risk, Tissue, Google Images, Medical imaging

US Nuclear’s (OTC-QB: UCLE) plan to bring medical isotopes to the market will reshape the landscape of healthcare and diagnostic imaging.

Key Points:

US Nuclear’s (OTC-QB: UCLE) plan to bring medical isotopes to the market will reshape the landscape of healthcare and diagnostic imaging.
Medical isotopes play a key role in various diagnostic and therapeutic applications, aiding in the detection and treatment of numerous medical conditions.
One of the most important functions of these isotopes is providing precise and accurate diagnostics for various medical conditions.
With the increased medical isotope production capacity provided by US Nuclear, people across the world in other countries can have access to these critical tools, addressing healthcare disparities and improving lives.

ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program

Retrieved on:

Tuesday, January 30, 2024

Isotope, ITM, RPT, DMF, Food, Cancer, Patient, Radiopharmaceutical, FDA

GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical stage biotechnology company developing differentiated and highly targeted radiopharmaceuticals, today announced the signature of a global master clinical supply agreement to support the development of Alpha-9’s Radiopharmaceutical Therapy (RPT) pipeline candidates for the treatment of cancer.

Key Points:

GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical stage biotechnology company developing differentiated and highly targeted radiopharmaceuticals, today announced the signature of a global master clinical supply agreement to support the development of Alpha-9’s Radiopharmaceutical Therapy (RPT) pipeline candidates for the treatment of cancer.
Under the terms of the agreement, ITM will supply its medical radioisotope, non-carrier-added Lutetium-177 (n.c.a.
177Lu for the clinical development of Alpha-9 radiopharmaceutical candidates comprising n.c.a.
ITM holds a U.S. Drug Master File (DMF) with the Food and Drug Administration (FDA) for n.c.a.